Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage


About this study

The purpose of this study is to see how much gabapentin will reduce headaches associated with subarachnoid hemorrhage (SAH) and to reduce the amount of narcotic pain medication prescribed.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. 18 years of age or older
  2. Have aneurysmal subarachnoid hemorrhage (aSAH) diagnosed by CT scan of the brain and/or angiogram evidence of intracranial aneurysm (CTA or digital subtraction angiogram or MRA)
  3. Have symptomatic headache
  4. Able to swallow and verbalize pain score
  5. No known allergy to gabapentin or fentanyl
  6. Numeric pain score ≥ 5
  7. Ability to provide written personal consent

Exclusion Criteria:

  1. Gabapentin use prior to SAH admission
  2. Renal failure with creatinine clearance less than 30 mL/min
  3. Unable to receive standard of care pain medications
  4. Pregnant or breastfeeding patients
  5. History of severe depression defined by DSM IV

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

William Freeman, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer